nach oben

Zeitschrift für Gerontologie und Geriatrie

Erschienen in:

23.09.2020 | Original Contributions

Risk of falls in patients with low bone mineral density

Analysis of placebo arms from clinical trials

verfasst von: Luis Möckel

Erschienen in: Zeitschrift für Gerontologie und Geriatrie | Ausgabe 6/2021

Einloggen, um Zugang zu erhalten

Abstract

Background

Falls are a major risk factor for osteoporotic fractures. Therefore, the aim of this study was to analyze the risk of falls in patients with low bone mineral density (BMD) and osteoporosis.

Methods

The risk of falls in patients with low BMD and/or osteoporosis was analyzed using data from placebo arms of clinical trials, indexed on clinicaltrials.gov. The risk was estimated using a single arm meta-analysis method and by applying a binary random effects model. In addition, meta-regression analyses were performed to identify associations between risk of falls and age, body mass index (BMI) and BMD.

Results

A total of 8762 patients from placebo arms of clinical trials were included into the analysis. Risk of falls was 5.2% (0.052, 95% confidence interval [95% CI] 0.022–0.082; n = 8714; I² = 97.3%, p ≤ 0.001) in patients with low BMD and/or osteoporosis and 5.9% (0.059, 95% CI 0.036–0.083; n = 7819; I² = 87.8%, p ≤ 0.001) in patients with osteoporosis. A significant association with risk of falls was identified for age in patients with low BMD and/or osteoporosis. BMD at total hip (TH; coefficient −0.077, 95% CI: −0.113–−0.040, p ≤ 0.001; n = 7715) and femoral neck (FN; coefficient −0.044, 95% CI −0.065–−0.023, p ≤ 0.001; n = 7662) were significantly associated with risk of falls in patients with osteoporosis.

Conclusion

This analysis identified the risk of falls in patients with low BMD and osteoporosis and an association of falls with age and BMD. Therefore, patients with osteoporosis need to receive mandatory fall risk mitigation measures, and the BMD at total hip or femoral neck could function as an indicator for the risk of falling.

Vorheriger Artikel Perturbation in public transport as a basic concept for perturbation-based balance training for fall prevention

Nächster Artikel German version of the outcome expectations for exercise scale-2

Adachi JD, Berger C, Barron R, Weycker D, Anastassiades TP et al (2019) Predictors of imminent non-vertebral fracture in elderly women with osteo-porosis, low bone mass, or a history of fracture, based on data from the population-based Canadian Multicentre Osteoporosis Study (CaMos). Arch Osteoporos 14:53PubMedCrossRef

Bonafede M, Shi N, Barron R, Li X, Crittenden DB et al (2016) Predicting imminent risk for fracture in patients aged 50 or older with osteoporosis using US claims data. Arch Osteoporos 11:26PubMedPubMedCentralCrossRef

Chen KW, Chang SF, Lin PL (2017) Frailty as a predictor of future fracture in older adults: a systematic review and meta-analysis. Worldviews Evid Based Nurs 14:282e93

Woolf AD, Akesson K (2003) Preventing fractures in elderly people. BMJ 327:89e95CrossRef

International Osteoporosis Foundation International Osteoporosis Foundation, Nyon (Switzerland). https://www.iofbonehealth.org/avoiding-falls;. Accessed 6 July 2020

Mitchell RJ, Lord SR, Harvey LA, Close JCT (2014) Associations between obesity and overweight and fall risk, health status and quality of life in older people. Aust N Z J Public Health 38:13–18. https://doi.org/10.1111/1753-6405.12152PubMedCrossRef

Cheng M‑H, Chang S‑F (2017) Frailty as a risk factor for falls among community dwelling people: evidence from a meta-analysis. J Nurs Scholarsh 00(0):1–8. https://doi.org/10.1111/jnu.12322CrossRef

Yeung SSY, Reijnierse EM, Pham VK, Trappenburg MC, Lim WK et al (2019) Sarcopenia and its association with falls and fractures in older adults: a systematic review and meta-analysis. J Cachexia Sarcopenia Muscle 10:485–500. https://doi.org/10.1002/jcsm.12411PubMedPubMedCentralCrossRef

McCloskey EV, Eastell R, McClung M, Pannacciulli N, Wand C et al (2019) A pooled analysis of fall incidence from placebo-controlled trials of Denosumab. In: Osteoporosis international 2019 Paris, France, Apr 4–7 (abstract OC29)

10.

Möckel L (2020) Weniger Stürze unter Teriparatid in Patienten mit Osteoporose: Eine Meta-Analyse. Osteologie 29:31–38. https://doi.org/10.1055/a-0979-2581CrossRef

11.

Armamento-Villareal R, Aguirre L, Napoli N, Shah K, Hilton T et al (2014) Changes in thigh muscle volume predict bone mineral density response to lifestyle therapy in frail, obese older adults. Osteoporos Int 25:551–558PubMedCrossRef

12.

De Sousa e Silva Araujo EC, Pagotto V, Aparecida Silveira E (2017) Association of bone mineral density with frailty, pre-frailty and osteoporosis in community-dwelling elderly: a prospective study. J Geriatr Med Gerontol 3:33

13.

Mera P, Laue K, Wei J, Berger JM, Karsenty G (2016) Osteocalcin is necessary and sufficient to maintain muscle mass in older mice. Mol Metab 5:1042–1047PubMedPubMedCentralCrossRef

14.

Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21:1539–1558PubMedCrossRef

15.

Higgins JPT, Green S (eds) (2011) Cochrane Handbook for Systematic Reviews of Intervention, Version 5.1.0. https://handbook-5-1.cochrane.org/front_page.htm. Accessed 4 July 2020

16.

Wallace BC, Dahabreh IJ, Trikalinos TA, Lau J, Trow P et al (2012) Closing the gap between methodologists and end-users: R as a computational back-end. J Stat Soft. https://doi.org/10.18637/jss.v049.i05CrossRef

17.

Viechtbauer W (2010) Conducting meta-analyses in R with the metafor package. J Stat Soft. https://doi.org/10.18637/jss.v036.i03CrossRef

18.

U.S. National Library of Medicine ClinicalTrials.gov. https://clinicaltrials.gov. Accessed 4 July 2020 (Study registry entries can be retrieved using the NCT numbers: NCT00439647, NCT00885170, NCT01575834, NCT00089791, NCT00729183, NCT01144377, NCT00112437, NCT00471237, NCT00433160, NCT02016716, NCT00896532, NCT00043186)

19.

Boonen S, Reginster J‑Y, Kaufman J‑M, Lippuner K, Zanchetta J et al (2012) Fracture risk and zoledronic acid therapy in men with osteoporosis. N Engl J Med 367:1714–1723. https://doi.org/10.1056/NEJMoa1204061PubMedCrossRef

20.

Cosman F, Crittenden DB, Adachi JD, Binkley N, Czerwinski E et al (2016) Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med 375:1532–1543. https://doi.org/10.1056/NEJMoa1607948CrossRefPubMed

21.

Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R et al (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361:756–765PubMedCrossRef

22.

Brixen K, Chapurlat R, Cheung AM, Keaveny TM, Fuerst T et al (2013) Bone density, turnover, and estimated strength in postmenopausal women treated with odanacatib: a randomized trial. J Clin Endocrinol Metab 98:571–580PubMedCrossRef

23.

Recker RR, Benson CT, Matsumoto T, Bolognese MA, Robins DA et al (2015) A randomized, double-blind phase 2 clinical trial of blosozumab, a sclerostin antibody, in postmenopausal women with low bone mineral density. J Bone Miner Res 30(2):216–224. https://doi.org/10.1002/jbmr.2351PubMedCrossRef

24.

Bone HG, McClung MR, Roux C, Recker RR, Eisman JA et al (2010) Odanacatib, a cathepsin‑K inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone density. J Bone Miner Res 25(5):937–947. https://doi.org/10.1359/jbmr.091035PubMedCrossRef

25.

Fitzpatrick LA, Dabrowski CE, Cicconetti G, Gordon DN, Papapoulos S et al (2011) The effects of ronacaleret, a calcium-sensing receptor antagonist, on bone mineral density and biochemical markers of bone turnover in postmenopausal women with low bone mineral density. J Clin Endocrinol Metab 96(8):2441–2449PubMedCrossRef

26.

Miyauchi A, Matsumoto T, Sugimoto T, Tsujimoto M, Warner MR et al (2010) Effects of teriparatide on bone mineral density and bone turnover markers in Japanese subjects with osteoporosis at high risk of fracture in a 24-month clinical study: 12-Month, randomized, placebo-controlled, double-blind and 12-month open-label phases. Bone 47:493–502. https://doi.org/10.1016/j.bone.2010.05.022PubMedCrossRef

27.

McClung MR, Grauer A, Boonen S, Bolognese MA, Brown JP et al (2014) Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med 370:412–420. https://doi.org/10.1056/NEJMoa1305224PubMedCrossRef

28.

McClung MR, Lewiecki M, Cohen SB, Bolognese MA, Woodson GC et al (2006) Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 354:821–831PubMedCrossRef

29.

Robbins AS et al (1989) Predictors of falls among elderly people. Results of two population-based studies. Arch Intern Med 149:1628–1633PubMedCrossRef

30.

Sheehan KJ, O’Connell MDL, Cunningham C, Crosby L, Kenn RA (2013) The relationship between increased body mass index and frailty on falls in community dwelling older adults. BMC Geriatr 13:132PubMedPubMedCentralCrossRef

31.

Möckel L, Treusch Y, Möckel C (2020) Regionale Unterschiede in der Häufigkeit osteoporotischer Frakturen des Femurs in Deutschland: Eine Analyse von Frakturfallzahlen aus der GBE-Datenbank. Osteologie. https://doi.org/10.1055/a-1085-3572CrossRef

Titel: Risk of falls in patients with low bone mineral density
Analysis of placebo arms from clinical trials
verfasst von: Luis Möckel
Publikationsdatum: 23.09.2020
Verlag: Springer Medizin
Erschienen in: Zeitschrift für Gerontologie und Geriatrie / Ausgabe 6/2021
Print ISSN: 0948-6704
Elektronische ISSN: 1435-1269
DOI: https://doi.org/10.1007/s00391-020-01784-5

Springerpflege

Abstract

Background

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2021

Ein neues Standardwerk zum Thema Schlaf

Schmerztherapie im Alter: Besonderheiten und Empfehlungen

Einflussfaktoren auf die Mortalität bei Patienten mit hüftgelenknahen Frakturen an einem regionalen Traumazentrum

Mitteilungen der DGGG

Die ersten Schritte nach einer hüftnahen Fraktur

Wie das Gehirn die Welt im Alter mit allen Sinnen wahrnimmt